Recruiting Alzheimers Disease Studies in London
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors....
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894)....
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are conside...
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to...
About Alzheimers Disease Clinical Trials in London
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 5 alzheimers disease clinical trials recruiting participants in London, ONTARIO. These studies are seeking a combined 1,055 participants. Research is being sponsored by BioNTech SE, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., Crinetics Pharmaceuticals Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in London — FAQ
Are there alzheimers disease clinical trials in London?
Yes, there are 5 alzheimers disease clinical trials currently recruiting in London, ONTARIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in London?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the London research site will contact you about next steps.
Are clinical trials in London free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many London studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 5 active trials in London are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov